Chumakov Center to produce 20 mln doses of CoviVac jab in 2022, says director general
The vaccine developed was registered with the Russian Health Ministry on February 19.
The Chumakov Center plans to produce 20 mln doses of the CoviVac vaccine against the novel coronavirus in 2022, Director General Aidar Ishmukhametov told TASS on Friday.
"We produced 6 mln doses of the CoviVac vaccine in 2021, whereas in 2022 we plan to produce 20 mln doses," he said.
The inactivated whole-virion CoviVac vaccine developed by the Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (known as the Chumakov Center) was registered with the Russian Health Ministry on February 19. Whole-virion vaccines are based either on artificially weakened viruses incapable of causing a disease or killed (inactivated) viruses.
Source
The Chumakov Center plans to produce 20 mln doses of the CoviVac vaccine against the novel coronavirus in 2022, Director General Aidar Ishmukhametov told TASS on Friday.
"We produced 6 mln doses of the CoviVac vaccine in 2021, whereas in 2022 we plan to produce 20 mln doses," he said.
The inactivated whole-virion CoviVac vaccine developed by the Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (known as the Chumakov Center) was registered with the Russian Health Ministry on February 19. Whole-virion vaccines are based either on artificially weakened viruses incapable of causing a disease or killed (inactivated) viruses.
Source